We create innovative genetics and data science solutions for companies, organizations, and ourselves.

  • Pharmacogenomics
  • Genotyping Array Design
  • Statistical Genetics
  • Medical Devices
  • Clinical Trial Design
  • Biomarker Development
  • Statistical Computing
  • Quality Assurance
  • Prediction Modeling
  • Biostatistics
  • Study Data Management
  • Pharmaceuticals

If you recently took advantage of the United States' National Institute on Drug Abuse's (NIDA) program offering free genotyping on our Smokescreen® genotyping array to substance abuse disorder investigators, remember to also take advantage of our full suite of services for clinical trials using biological markers (biomarkers). You can also learn more about Smokescreen in BMC Genomics.


Designed specifically for researchers interested in the causes of addiction and its treatment.

More addiction-related content than any other commercially available array

  • Covers 98% of common genetic variation in 1000+ addiction genes

  • More than 296K markers, selected for African, East Asian, and European populations

  • More than 20K markers from expert nomination, knowledge-bases, candidate gene arrays, and the literature

More nicotine and tobacco related content than any other commercially available array

  • More than 11K markers in the nicotine acetylcholine receptor gene cluster3 and nicotine metabolizer regions4
  • More than 16K markers for related co-morbidities and diseases

Better genome-wide imputation coverage of common variants than most similarly-sized arrays

  • African (66%), East Asian (82%), and European (91%)
The Smokescreen® genotyping array  is comprehensive, cost-efficient, cutting-edge, easy to use, elegant, and powerful. 

The Smokescreen® genotyping array  is comprehensive, cost-efficient, cutting-edge, easy to use, elegant, and powerful. 

1 Developed with support from the United States National Institute on Drug Abuse (NIDA).
2 For research use only. Not for use in diagnostic procedures.

Featured Articles

Biostatistics and Clinical Trials:
An Interview with BioRealm's Carolyn Ervin, PhD

In this interview with Carolyn Ervin, biostatistician, and co-founder of BioRealm, we discuss how to get the most value from experienced biostatisticians, developments in the industry and her associated concerns, a few of her favorite tools when working on clinical trials, and project management secrets.

Estimated reading time: 4 minutes, 51 seconds

Biological Markers and Clinical Trials:
An Interview with BioRealm's James Baurley, PhD

In this interview with James Baurley, data scientist, and co-founder of BioRealm, LLC., we discuss how biological markers, especially genetic biological markers, may be used in clinical trials, and a few of the computational and statistical issues and limitations.

Estimated reading time: 4 minutes, 43 seconds

We’ve built a diverse team of experts from leading companies and research universities, and we have some of the best advisors in the industry. Get in touch with us today for a free consultation.


James W. Baurley, PhD
Founding Partner
Data Science

Carolyn M. Ervin, PhD
Founding Partner


Andrew Bergen, PhD
Genetic Epidemiology


Conor Ryan
Software Engineering

Carissa Pardamean, MS
Data Analysis

Brian Malone
Client and Investor

Strategic Partners

BioRealm is fortunate to call industry-leading strategic partners our friends and colleagues. These partners augment our full-time staff when we feel their experience will benefit our clients.

David Conti, PhD
Statistical Genetics

Doug Levinson, JD, MBA
Business Affairs

Bens Pardamean, PhD
Asia Pacific Region


"Because of the SmokeScreen® array, we have the ability to reveal genetic information previously hidden in NIDA's samples. We have great confidence in SmokeScreen® ‒ it is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."

— Dr. Andrew Brooks, RUCDR Infinite Biologics’ Chief Operating Officer and Director of Technology Development

“We are excited to be part of BioRealm’s vision of improving human health by providing insight into the genetics of tobacco-related illness. It was a pleasure to work with BioRealm’s team of dedicated scientists to co-develop this cutting-edge technology.”

— Dr. Frank R. Witney, President and Chief Executive Officer of Affymetrix